PD-1/PD-L1抑制剂领域技术创新态势及其科学基础研究

Technological Innovation and Its Scientific Basis of PD-1/PD-L1 Inhibitors

目的:通过对PD-1/PD-L1抑制剂的专利分析来揭示其技术创新态势及科学基础来源。方法:采用专利计量分析结合定性分析的方法对PD-1/PD-L1抑制剂的专利从时间趋势、区域分布、技术开发热点及其网络分析等角度进行分析。结果与结论:PD-1/PD-L1抑制剂领域共有专利申请5502项,专利申请逐年增长;技术开发主要集中在美国和中国;技术开发热点以活性和抗体研究为主,且抗肿瘤活性研究的竞争优势相对较强;科学基础研究主题主要集中在三个方向,即肿瘤免疫联合治疗、PD-1/PD-L1通路在肿瘤免疫逃逸中的机制研究、PD-1/PD-L1抑制剂在非小细胞肺癌中的临床研究。通过对PD-1/PD-L1抑制剂领域的专利进行分析,揭示其技术创新态势及其科学基础来源,从情报学角度为肿瘤免疫治疗研发提供信息支撑。

Objective:To discuss the technological innovation trend and its scientific basis of PD-1/PD-L1 inhibitors through patent analysis.Methods:A combination of qualitative and quantitative patent analysis was used to analyze PD-1/PD-L1 inhibitor patents in terms of time trend,regional distribution,hotspots of technology development and network analysis.Results and Conclusion:The results show that there were 5502 patent applications in the field of PD-1/PD-L1 inhibitors,and patent applications have been increasing year by year.Technology development was mainly concentrated in the United States and China;technology development hotspots focused on activity and antibody research,and the competitive advantage of antitumor activity research was relatively strong.The research topics of scientific basis were mainly concentrated on three directions:combined cancer immunotherapy,the mechanism of PD-1/PD-L1 pathway in tumor immune escape,and the clinical study of PD-1/PD-L1 inhibitors in non-small cell lung cancer.This article discusses the technological innovation trend and its scientific basis of PD-1/PD-L1 inhibitors from the perspective of information science based on patent analysis,and provides information support for cancer immunotherapy research and development.